bioRxiv ScienceSearch

bioRxiv · 10.1101/347278

A novel green approach for treatment of immature Schistosomiasis Mansoni infection in mice; Arabic gum (Acacia Senegal) antischistosomal properties

Abstract

Schistosomiasis is one of the most socioeconomically exhausting parasitic infection in tropical and subtropical areas. Praziquantel (PZQ), the only common schistosocidal drug in use, is not efficient enough for treatment of immature infection. Arabic gum (AG) is a complex polysaccharide acts as anti-oxidant which modulates the inflammatory and/or immunological processes. This study explores for the first time, the antischistosomal properties of AG in mice infected with the immature stage of Schistosoma mansoni. Mice were divided into four groups: control group (infected non-treated), AG treated group, PZQ treated group, and AG+PZQ treated group. Oral administration of AG in a dose of 1gm/kg body weight, daily for 3 consecutive weeks post-infection (p.i.) resulted in a statistically significant lower worm burden in both AG group and AG+PZQ group compared to PZQ and control groups. AG+PZQ group always showed the best performance when compared with other groups regarding tissue egg load and oogram pattern. AG, both alone and in combination with PZQ, decreased the number, diameter; increased the cellularity and the number of degenerated Schistosoma eggs inside granulomas. Results obtained by this work elucidated a promising AG bioactivity against S. mansoni immature stages and provided a platform for subsequent experimental studies to illuminate the academia more about this novel and \"green\" antischistosomal agent.\n\nAuthor summarySchistosomiasis is a major public health threat in many parts of the world, it affects more than 240 million people in more than 70 countries and almost 800 million people are at risk of acquiring this disease. Serious consequences and disabilities might result from untreated schistosomiasis such as hepatosplenic fibrosis with portal hypertension, gastrointestinal hemorrhage and death.\n\nSchistosomiasis control is focused on periodic treatment with praziquantel (PZQ). However, PZQ has only moderate action against young developing stages of schistosomula. Recently, resistance has emerged to PZQ. Therefore, chemotherapy alone is unlikely to reduce infection levels of schistosomiasis. Several practical approaches have been suggested to augment treatment programs. Of course, the development of a complementary treatment would contribute enormously to the reduction of schistosomiasis. Recently, natural products have been popular and attracted most of the attention as it could offer new effective therapy against schistosomiasis. Arabic gum (AG) is an edible, dried sticky exudate from Acacia Senegal, which is used in this study to assess the AG antischistosomal properties. Our study revealed that AG has an excellent statistically significant effect against immature murine schistosomiasis, both alone and in combination with PZQ. This approach may point to novel targets for treatment of schistosomiasis.

Explore related subjects

Keep this discovery

BibTeXRIS

selem, r., Rashed, S., Younis, M., Hussien, B., Saffeyeldin Mohamed, F., Elmohamady, A., EL-kholy, A., Rashed, G., Kishik, S., Moharm, A., Nageeb, M., Kardoush, M. I.. 2018-06-14. A novel green approach for treatment of immature Schistosomiasis Mansoni infection in mice; Arabic gum (Acacia Senegal) antischistosomal properties. https://doi.org/10.1101/347278

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

A conserved cysteine-histidine-glutamate metal site identifies DUF501 (Rv1025), an essential uncharacterised protein family of Mycobacterium tuberculosis, as a candidate metalloenzyme and drug target

A substantial fraction of the Mycobacterium tuberculosis proteome remains functionally uncharacterised. Rv1025, a 155-residue protein carrying the domain of unknown function DUF501 (Pfam PF04417), is essential by transposon mutagenesis and vulnerable by CRISPR interference, an attractive but neglected drug target, yet has never been functionally described. The family (4,370 proteins, no Gene Ontology term, no solved structure) is uncharacterised across all organisms and essential in three Actinobacterial genera. A Foldseek search of the AlphaFold model against complete structural databases finds no significant homolog, indicating a novel fold. The operon eno-divIC-Rv1025-ppx2 is conserved across the Actinobacteria phylum, yet AlphaFold-Multimer finds no direct complex between Rv1025 and its neighbour DivIC. Instead, conservation across 8,700 homologous sequences reveals a near-invariant Cys113-His115-Glu59 cluster forming a pocket. Holo AlphaFold3 predictions with Zn, Fe and Mn confidently place a divalent metal on this triad at 2.25-2.47 A; mutating the triad relocates the metal, and an independent backbone-geometry predictor recovers the same site, confirming specificity. The triad is universal across the family: present in all 1,472 near-complete bacterial sequences of the Pfam alignment, with no non-conservative substitution among the 2,228 sequences examined, a defining feature of bacterial DUF501 rather than a mycobacterial peculiarity. We propose that DUF501 is a metal-binding protein and candidate metalloenzyme, the first functional hypothesis for this family, whose conserved, essential metal pocket is a promising drug target. As the predictions build on a conservation-defined site within a fully computational study, they are supportive rather than proof of metal occupancy and warrant experimental validation.

microbiology

Mycoplasmal endosymbionts of Trichomonas vaginalis are associated with reduced risk for Chlamydia trachomatis endometrial infection in asymptomatic, coinfected, women.

Trichomonas vaginalis is a protozoan parasite that causes trichomoniasis, the most common curable non-viral sexually transmitted infection, and Chlamydia trachomatis is a bacterial pathogen that can ascend to the upper genital tract and cause pelvic inflammatory disease, infertility, and ectopic pregnancy. T. vaginalis harbors bacterial endosymbionts, including Candidatus Malacoplasma girerdii, an obligate symbiont, and Metamycoplasma hominis, which can live freely or symbiotically. In a 16S rRNA sequencing study of the cervicovaginal microbiome of women at high risk for chlamydial infection, Ca. M. girerdii abundance was one of 13 features predicting lack of chlamydial spread to the endometrium, despite no direct association between T. vaginalis infection and reduced chlamydial ascension. Investigating the relationship between these microorganisms further, we found that T. vaginalis vaginal abundance correlated positively with chlamydial burden in women whose infection was confined to the cervix, while a nonsignificant inverse relationship was seen in women with endometrial spread. Among participants with high chlamydial burden, Ca. M. girerdii was detected exclusively in women without endometrial infection. Both endosymbionts trended toward more frequent detection, and higher abundance, in coinfected women without endometrial spread, while M. hominis abundance correlated strongly with T. vaginalis burden in this group. These findings suggest that mycoplasmal endosymbionts of T. vaginalis, rather than T. vaginalis itself, are microbial factors limiting chlamydial ascension, and point to a three-way interaction between parasite, endosymbiont, and bacterial pathogen that shapes upper genital tract C. trachomatis infection risk.

microbiology

Understanding the physiological alterations of Vibrio cholerae upon exposure to L-ascorbic acid

The scourge of cholera remains a major global public health threat. It affects up to 4 million people worldwide and causes tens of thousands of deaths each year. The disease is experiencing a concerning resurgence in many parts of Africa, the Middle East, and Asia. To effectively tackle cholera and circumvent rising antimicrobial resistance, targeted biological and preventive approaches, complementing traditional rehydration, are urgently needed. In this regard, our group has demonstrated the efficacy of L-ascorbic acid in controlling the growth and pathogenesis of Vibrio cholerae in vitro. The present work further provides a mechanistic elucidation of the L-ascorbic acid-mediated physiological changes in V. cholerae and also bolsters such a non-antibiotic approach to control cholera.

microbiology